Increasing the Usefulness of COAs in Heart Failure Research
Dr. Bill Byrom and Professor Julian Gillmore discuss advancing COAs in heart failure trials, including new treatments, and limitations of the 6MWT.
Dr. Bill Byrom and Professor Julian Gillmore discuss advancing COAs in heart failure trials, including new treatments, and limitations of the 6MWT.
Dr. Bill Byrom and Professor Marianna Fontana discuss enhancing COAs in heart failure trials, focusing on 6MWT, actigraphy, and sensor-derived...
Explore PFDD, a transformative approach that incorporates patient insights into every stage of the drug life cycle, enhancing outcomes and efficiency.